Beta-adrenergic receptors are expressed across diverse cancers
Based largely on retrospective analyses and a handful of prospective case reports, pharmacological inhibition of the beta adrenergic receptors using beta blockers has shown clinical anti-cancer efficacy in reproductive cancers, as well as angiosarcoma and multiple myeloma. Because of the potential p...
Saved in:
Published in | Oncoscience Vol. 4; no. 7-8; pp. 95 - 105 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
United States
Impact Journals LLC
23.08.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Based largely on retrospective analyses and a handful of prospective case reports, pharmacological inhibition of the beta adrenergic receptors using beta blockers has shown clinical anti-cancer efficacy in reproductive cancers, as well as angiosarcoma and multiple myeloma. Because of the potential promise of beta blockers as an adjunct to standard anti-cancer therapy, it is imperative to identify other tumor types expressing beta adrenergic (β-AR) receptors so future preclinical and clinical studies can be directed at the most promising tumor targets. We performed immunohistochemical detection of β1-AR, β2-AR, and β3-AR across 29 of the most common human cancer types (389 tissues total) and 19 matching non-diseased controls (100 tissues total). Our analysis revealed all three β-AR receptors were expressed most strongly in melanoma relative to other cancer types. Other malignancies that revealed relatively higher levels of β-AR receptors were esophagus, pancreas, kidney, and lung cancers. Moreover, particular β-AR receptors exhibited significant overexpression in tumor tissue relative to their matching normal tissue in urogenital/reproductive malignancies including breast, endometrium, ovarian, and urothelial cancer, as well as colon, lung, and thyroid cancer. This study identifies several cancer types expressing the β-AR receptors which should be evaluated in future studies for susceptibility to beta blockade. |
---|---|
AbstractList | Based largely on retrospective analyses and a handful of prospective case reports, pharmacological inhibition of the beta adrenergic receptors using beta blockers has shown clinical anti-cancer efficacy in reproductive cancers, as well as angiosarcoma and multiple myeloma. Because of the potential promise of beta blockers as an adjunct to standard anti-cancer therapy, it is imperative to identify other tumor types expressing beta adrenergic (β-AR) receptors so future preclinical and clinical studies can be directed at the most promising tumor targets. We performed immunohistochemical detection of β1-AR, β2-AR, and β3-AR across 29 of the most common human cancer types (389 tissues total) and 19 matching non-diseased controls (100 tissues total). Our analysis revealed all three β-AR receptors were expressed most strongly in melanoma relative to other cancer types. Other malignancies that revealed relatively higher levels of β-AR receptors were esophagus, pancreas, kidney, and lung cancers. Moreover, particular β-AR receptors exhibited significant overexpression in tumor tissue relative to their matching normal tissue in urogenital/reproductive malignancies including breast, endometrium, ovarian, and urothelial cancer, as well as colon, lung, and thyroid cancer. This study identifies several cancer types expressing the β-AR receptors which should be evaluated in future studies for susceptibility to beta blockade. |
Author | Rains, Steven L Bryan, Brad A Amaya, Clarissa N |
AuthorAffiliation | 1 Department of Biomedical Sciences, Texas Tech University Health Sciences Center, El Paso, TX, USA |
AuthorAffiliation_xml | – name: 1 Department of Biomedical Sciences, Texas Tech University Health Sciences Center, El Paso, TX, USA |
Author_xml | – sequence: 1 givenname: Steven L surname: Rains fullname: Rains, Steven L organization: Department of Biomedical Sciences, Texas Tech University Health Sciences Center, El Paso, TX, USA – sequence: 2 givenname: Clarissa N surname: Amaya fullname: Amaya, Clarissa N organization: Department of Biomedical Sciences, Texas Tech University Health Sciences Center, El Paso, TX, USA – sequence: 3 givenname: Brad A surname: Bryan fullname: Bryan, Brad A organization: Department of Biomedical Sciences, Texas Tech University Health Sciences Center, El Paso, TX, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28966942$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkEtrwzAQhEVJadI0956K_oBTaWVb8iXQhvQBgV5yN2tpk7okkpHc0P77GvogPc3AMt-wc8lGPnhi7FqKuTSlgtvgbUi2JW9prgp9xiaglMxyrfToxI_ZLKU3IYTMwaiiuGBjMFVZVjlM2OKeeszQRfIUd63lkSx1fYiJYyROH12klMhxtDGkxF17pJiIWxxaY7pi51vcJ5r96JRtHlab5VO2fnl8Xt6ts04byCQSgLHKaZIaUeRWSwXl8IQAJ51xtmqwaSqtK5R5I0FILHLjGuMq3Cqtpmzxje3emwM5S76PuK-72B4wftYB2_r_xbev9S4c66KUJQgYADengL_k7xDqC93qZh4 |
ContentType | Journal Article |
Copyright | Copyright: © 2017 Rains et al. 2017 |
Copyright_xml | – notice: Copyright: © 2017 Rains et al. 2017 |
DBID | NPM 5PM |
DOI | 10.18632/oncoscience.357 |
DatabaseName | PubMed PubMed Central (Full Participant titles) |
DatabaseTitle | PubMed |
DatabaseTitleList | PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2331-4737 |
EndPage | 105 |
ExternalDocumentID | 28966942 |
Genre | Journal Article |
GroupedDBID | ADBBV ADRAZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL DIK HYE KQ8 M48 NPM OK1 PGMZT RPM 5PM |
ID | FETCH-LOGICAL-p782-1ae228c3d7e17aa04c7132686302d1d8dc9babb9779a14b1201a548db8d9af373 |
IEDL.DBID | RPM |
ISSN | 2331-4737 |
IngestDate | Tue Sep 17 21:17:03 EDT 2024 Sat Sep 28 08:02:17 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 7-8 |
Keywords | beta adrenergic beta blocker cancer |
Language | English |
License | This article is distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-p782-1ae228c3d7e17aa04c7132686302d1d8dc9babb9779a14b1201a548db8d9af373 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616202/ |
PMID | 28966942 |
PageCount | 11 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5616202 pubmed_primary_28966942 |
PublicationCentury | 2000 |
PublicationDate | 20170823 |
PublicationDateYYYYMMDD | 2017-08-23 |
PublicationDate_xml | – month: 8 year: 2017 text: 20170823 day: 23 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Oncoscience |
PublicationTitleAlternate | Oncoscience |
PublicationYear | 2017 |
Publisher | Impact Journals LLC |
Publisher_xml | – name: Impact Journals LLC |
References | 27788481 - Oncotarget. 2016 Nov 22;7(47):77825-77837 192402 - Br J Pharmacol. 1977 Apr;59(4):577-83 25375203 - Oncotarget. 2014 Oct 30;5(20):10058-69 27100060 - Pediatr Blood Cancer. 2016 Jul;63(7):1290-2 8935711 - Naunyn Schmiedebergs Arch Pharmacol. 1996 Mar;353(4):438-44 27468364 - AJP Rep. 2016 Jul;6(3):e260-3 8395693 - Psychopharmacol Ser. 1993;10:9-14 27733010 - Am J Hematol. 2017 Jan;92 (1):50-55 27408442 - Indian J Hematol Blood Transfus. 2016 Jun;32(Suppl 1):370-1 23360994 - Nat Commun. 2013;4:1403 27737446 - JAMA Facial Plast Surg. 2017 Mar 1;19(2):102-107 27035124 - Oncol Rep. 2016 Jun;35(6):3135-42 25693013 - N Engl J Med. 2015 Feb 19;372(8):735-46 1692931 - J Cardiovasc Pharmacol. 1990 May;15(5):720-8 6036174 - Nature. 1967 May 6;214(5088):597-8 23905034 - Transl Med UniSa. 2011 Oct 17;1:213-28 22743651 - Mod Pathol. 2012 Nov;25(11):1446-51 26375166 - JAMA Dermatol. 2015 Nov;151(11):1226-9 28004027 - JAAD Case Rep. 2016 Dec 07;2(6):497-499 23170111 - Exp Ther Med. 2012 Oct;4(4):594-604 8254011 - J Clin Invest. 1993 Dec;92(6):2564 23555867 - PLoS One. 2013;8(3):e60021 27792834 - Br J Pharmacol. 2017 Jan;174(2):139-149 22998044 - Curr Drug Deliv. 2013 Feb;10(1):64-6 25624880 - Ecancermedicalscience. 2015 Jan 08;9:499 7491992 - Am J Physiol. 1995 Nov;269(5 Pt 1):L709-14 27582542 - Oncotarget. 2016 Oct 18;7(42):68314-68327 26301456 - Cancer. 2015 Oct 1;121(19):3444-51 18550886 - N Engl J Med. 2008 Jun 12;358(24):2649-51 10926562 - Am J Physiol Lung Cell Mol Physiol. 2000 Aug;279(2):L379-89 27211551 - EBioMedicine. 2016 Apr;6:87-95 28031536 - Oncotarget. 2017 Jan 24;8(4):6446-6460 |
References_xml | |
SSID | ssj0001428355 |
Score | 2.0911431 |
Snippet | Based largely on retrospective analyses and a handful of prospective case reports, pharmacological inhibition of the beta adrenergic receptors using beta... |
SourceID | pubmedcentral pubmed |
SourceType | Open Access Repository Index Database |
StartPage | 95 |
SubjectTerms | Research Paper |
SummonAdditionalLinks | – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV09T8MwELWgLCwIxFf5kgfWlMR2nXgABIiqQipTK3WrzvFFIKG0TYtU_j1nNxQqdWKLlHjw2ef3zrl7x9i1IhQnmPNlv5hGqqAnI00eSamV1iYHGy5zeq-6O1Avw_bwtzy6NuBsY2jn-0kNqo_WYvp1Tw5_6x0-01LcjMu8Vn7Elmyn22xHKKn8fu_VZD_cuARtsXb9r3LTQK8MnBH_N75x-wqQ1pMl_6BPZ5_t1bSRPyzX-YBtYXnI7h5xDhH4Wmys6ATjdHrhxLfP4VAhx0VIckXHIWAhdyEHA3nuV7qaHbF-57n_1I3qfgjRhHA8SgCFyHLpUkxSgFjlFGAKTROJhUtc5nJjwVoidAYSZROCdqB4xNnMGShkKo9ZoxyXeMo4xRBF7BKIXaGUlGAQfWO_RNgYDUhospPlpEeTpebF6McuTZaumWP1gZepXn9Tvr8FuWpiaFrE4uzfI8_ZrvBgGpNPywvWmFefeElUYG6vwgp_A_K-t_M priority: 102 providerName: Scholars Portal |
Title | Beta-adrenergic receptors are expressed across diverse cancers |
URI | https://www.ncbi.nlm.nih.gov/pubmed/28966942 https://pubmed.ncbi.nlm.nih.gov/PMC5616202 |
Volume | 4 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSwMxEA5tT15E8VUfJQev230k-8hF0GIpQsVDhd7KJJnFgl2XtYI_30m6Le3V20J2Icmw-fIl38zH2L0kFCeYc2m_mAeypCcllAmEyGSWKQPaH-ZMX7PJu3yZp_MOS7e5MF60b_RyWH2uhtXyw2sr65UJtzqx8G06IszPiLSHXdbNhdij6P5gxZcQS9srySITSfhVmbYyJA5F6nz3iGZQT5w_-w53DjWReyAzPmHH7e6QP256cco6WJ2xhydcQwAu5RobWqg4LVJYO5ccDg1y_PVaVrQcPORx66UWyI0LaPN9zmbj59loErS2B0FNcB3EgElSGGFzjHOASBrikUlGA4kSG9vCGqVBa9q3KYiljgnBgWiH1YVVUIpcXLBe9VXhFeNEFcrIxhDZUkohQCE6_7440REqENBnl5tBL-pNaYvFdl76LD-Yjt0Lrhr1YQsFyVelboNy_e8vb9hR4jAzol9X3LLeuvnBO0L8tR6w7lQWAx_nP_WKr3Y |
link.rule.ids | 230,315,733,786,790,891,2236,24346,27955,27956,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwELVKOcCFRWxlzYFrVme9IEFFVaCtOBTUW-VlKipoGoVUQnw9YyepWm5wi-REcp6cefOc5xlCrn1kcaQ5dewXItOf4FVCE2FSGvphmAjG9WZOfxB2X_zHUTBqkKA-C6NN-4JPrfRjZqXTN-2tzGbCrn1i9nO_jZwfomi3N8gmfq9esCLS9daKLiIWVD8l45B69jwVVW1IsGigOu-h0MC5qA7tS-ZZd0Wu0Exnl7zWEyzdJe_WouCW-P5Vu_HPb7BHdqrE07gth_dJA9IDcnMHBTOZOs0NOcZAA-MfZKoBj8FyMOBL22RBGkyzqSG1iwMModZK_nlIhp37YbtrVh0VzAwzAdNl4HmxoDICN2LM8QVKVC9EhBxPujKWIuGMc0wJE-b63MXkgKGikTyWCZvQiB6RZjpP4YQYqEImjnSZIye-TylLAFRrQNfjDiSMshY5LtEcZ2XVjHENeItEazgvb1CFrtdHED1d8LpC6_TfT16Rre6w3xv3HgZPZ2TbU9TsYISg56RZ5Au4wMSi4Jd6Gf0ASNHQiA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JS8NAFB60gnhxwa2uc_CaddIsF0GrpS4tPVQoXsosL1i0aYgpiL_eN9O0tB57C2QCk8fkfe-bfPM-Qm4CRHGEOX3sFyIrSPEqYYm0GAuDMEwkF2Yzp9MN22_B86AxWLL6MqJ9KUZ29jW2s9GH0VbmY-nMdWJOr9NEzA-RtDu5Sp1NsoXfrB8tEXWzvWIaiTWqH5NxyHxnksmqPyTYrKHd95Bs4Hy0S_sCfVaVkUtQ09oj7_NJzhQmn_a0FLb8_de_ca232Ce7VQFK72ZDDsgGZIfk9h5KbnF9qhsKzIUU8yDk2oiH8gIo_Bi5LCjKDapSZdQcQKVeM8X3Eem3HvvNtlU5K1g5VgSWx8H3Y8lUBF7EuRtIpKp-iFFyfeWpWMlEcCGwNEy4FwgPiwSOzEaJWCU8ZRE7JrVsksEpochGUld53FVpEDDGEwBtEej5woWEM14nJ7OIDvNZ94zhPOh1Eq3EejFAN7xevYMRNI2vq4idrf3kNdnuPbSGr0_dl3Oy42uEdjFRsAtSK4spXGJ9UYors5L-ANq40wg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Beta-adrenergic+receptors+are+expressed+across+diverse+cancers&rft.jtitle=Oncoscience&rft.au=Rains%2C+Steven+L.&rft.au=Amaya%2C+Clarissa+N.&rft.au=Bryan%2C+Brad+A.&rft.date=2017-08-23&rft.pub=Impact+Journals+LLC&rft.eissn=2331-4737&rft.volume=4&rft.issue=7-8&rft.spage=95&rft.epage=105&rft_id=info:doi/10.18632%2Foncoscience.357&rft_id=info%3Apmid%2F28966942&rft.externalDBID=PMC5616202 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2331-4737&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2331-4737&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2331-4737&client=summon |